RU2018110064A - Антитела к бета-амилоиду - Google Patents
Антитела к бета-амилоиду Download PDFInfo
- Publication number
- RU2018110064A RU2018110064A RU2018110064A RU2018110064A RU2018110064A RU 2018110064 A RU2018110064 A RU 2018110064A RU 2018110064 A RU2018110064 A RU 2018110064A RU 2018110064 A RU2018110064 A RU 2018110064A RU 2018110064 A RU2018110064 A RU 2018110064A
- Authority
- RU
- Russia
- Prior art keywords
- antibody molecule
- seq
- human
- molecule according
- selected antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (20)
1. Выделенная молекула антитела, которая является селективной в отношении связывания человеческого бета-амилоидного 1-42 пептида (Aβ1-42), а не человеческого бета-амилоидного 1-40 пептида (Aβ1-40), где молекула антитела содержит:
(i) VH-домен, содержащий следующие HCDR:
HCDR1 SEQ ID NO: 525,
HCDR2 SEQ ID NO: 526 и
HCDR3 SEQ ID NO: 527; и
(ii) VL-домен, содержащий следующие LCDR:
LCDR1 SEQ ID NO: 534
LCDR2 SEQ ID NO: 535 и
LCDR3 SEQ ID NO: 536;
и где VL-домен имеет треонин в аминокислотном положении, соответствующем положению 81 в SEQ ID NO: 29.
2. Выделенная молекула антитела по п. 1, где VH-домен имеет аргинин в аминокислотном положении, соответствующем положению 43 в SEQ ID NO: 20.
3. Выделенная молекула антитела по п.1 или 2, где молекула антитела способна связывать растворимый мономерный человеческий Aβ1-42 с константой диссоциации (KD) 500 Пм.
4. Выделенная молекула антитела по любому из пп.1-3, где молекула антитела способна связывать n-олигомер с небольшим количеством звеньев (до пентамера) человеческого Aβ1-42 с константой диссоциации (KD) 500 Пм.
5. Выделенная молекула антитела по любому из пп.1-4, где молекула антитела либо не связывает Aβ1-40, либо связывает Aβ1-40 с KD более, чем 1 мМ.
6. Выделенная молекула антитела по любому из пп.1-5, где молекула антитела представляет собой моноклональное антитело.
7. Выделенная молекула антитела по любому из пп.1-5, где молекула антитела представляет собой scFv.
8. Выделенная молекула антитела по любому из пп.1-5, где молекула антитела представляет собой Fab.
9. Способ лечения человека или животного, нуждающегося в этом, включающий введение указанному субъекту антитела по любому из пп.1-8.
10. Способ по п.9, где лечение по меньшей мере снижает амилоидоз, лечит болезнь Альцгеймера, улучшает когнитивную деятельность или замедляет снижение когнитивных способностей у пациента, страдающего болезнью Альцгеймера или синдромом Дауна, и/или лечит макулярную дегенерацию.
11. Способ по п.9, где способ снижает амилоидоз.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713996P | 2012-10-15 | 2012-10-15 | |
| US61/713,996 | 2012-10-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015118180A Division RU2651486C2 (ru) | 2012-10-15 | 2013-10-15 | Антитела к бета-амилоиду |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018110064A3 RU2018110064A3 (ru) | 2019-02-28 |
| RU2018110064A true RU2018110064A (ru) | 2019-02-28 |
| RU2689674C2 RU2689674C2 (ru) | 2019-05-28 |
Family
ID=49765450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018110064A RU2689674C2 (ru) | 2012-10-15 | 2013-10-15 | Антитела к бета-амилоиду |
| RU2015118180A RU2651486C2 (ru) | 2012-10-15 | 2013-10-15 | Антитела к бета-амилоиду |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015118180A RU2651486C2 (ru) | 2012-10-15 | 2013-10-15 | Антитела к бета-амилоиду |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US9834598B2 (ru) |
| EP (2) | EP2906597B1 (ru) |
| JP (5) | JP6343615B2 (ru) |
| KR (2) | KR102308915B1 (ru) |
| CN (2) | CN110294804B (ru) |
| AU (3) | AU2013333948B2 (ru) |
| BR (1) | BR112015008347B1 (ru) |
| CA (1) | CA2888322A1 (ru) |
| CY (1) | CY1122987T1 (ru) |
| DK (1) | DK2906597T3 (ru) |
| ES (1) | ES2802873T3 (ru) |
| HK (1) | HK1213906A1 (ru) |
| HR (1) | HRP20200936T1 (ru) |
| HU (1) | HUE051127T2 (ru) |
| LT (1) | LT2906597T (ru) |
| ME (1) | ME03751B (ru) |
| MX (2) | MX370725B (ru) |
| PL (1) | PL2906597T3 (ru) |
| PT (1) | PT2906597T (ru) |
| RS (1) | RS60388B1 (ru) |
| RU (2) | RU2689674C2 (ru) |
| SI (1) | SI2906597T1 (ru) |
| WO (1) | WO2014060444A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2689674C2 (ru) * | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
| CN107531781B (zh) * | 2015-01-29 | 2021-12-07 | 抗菌技术,生物技术研究与发展股份有限公司 | 用于阿尔茨海默病和相关紊乱的抗体分子和肽递送*** |
| JP6920293B2 (ja) | 2015-10-30 | 2021-08-18 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ＩｇＧ軽鎖におけるＮ末端切断の防止 |
| KR20180119670A (ko) * | 2016-03-15 | 2018-11-02 | 아스트라제네카 아베 | 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합 |
| KR20230165883A (ko) * | 2016-06-07 | 2023-12-05 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | 알츠하이머병의 치료 방법 |
| WO2020015637A1 (zh) * | 2018-07-17 | 2020-01-23 | 江苏恒瑞医药股份有限公司 | 抗Abeta抗体、其抗原结合片段及应用 |
| CN111454980A (zh) * | 2020-04-14 | 2020-07-28 | 郑州师范学院 | 重组载体的构建方法及其构建的重组载体及应用 |
| TW202216188A (zh) | 2020-06-25 | 2022-05-01 | 英商梅迪繆思有限公司 | 軸突損傷之預防 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| KR102565470B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물 |
| KR102565471B1 (ko) * | 2022-08-04 | 2023-08-10 | 가천대학교 산학협력단 | 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물 |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| CN116716351B (zh) * | 2023-03-30 | 2024-02-23 | 湖北天勤生物技术研究院有限公司 | 用于构建食蟹猴阿尔兹海默症模型的组合物及其应用和构建方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
| US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5185243A (en) | 1988-08-25 | 1993-02-09 | Syntex (U.S.A.) Inc. | Method for detection of specific nucleic acid sequences |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| ATE311444T1 (de) | 2000-03-31 | 2005-12-15 | Cambridge Antibody Tech | Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1519740A4 (en) * | 2001-08-17 | 2005-11-09 | Lilly Co Eli | FASTER IMPROVEMENT OF COGNITION IN DISEASES ASSOCIATED WITH A-BETA |
| EP1497321B1 (en) * | 2002-04-19 | 2011-06-29 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
| EP1717250A4 (en) * | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
| CA2584608C (en) * | 2004-03-29 | 2015-03-17 | The University Court Of The University Of Aberdeen | Specific binding members against synaptophysin |
| US8168188B1 (en) * | 2004-08-11 | 2012-05-01 | Kyoto University | Antibody and utilization of the same |
| CN101076543A (zh) * | 2004-10-13 | 2007-11-21 | 阿布林克斯公司 | 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽 |
| PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
| GB0500099D0 (en) | 2005-01-05 | 2005-02-09 | Cambridge Antibody Tech | Methods and means relating to protein variants |
| ES2318918B1 (es) * | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| WO2008011348A2 (en) * | 2006-07-14 | 2008-01-24 | Ac Immune S.A. | Humanized antibody against amyloid beta |
| US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
| US20090175847A1 (en) * | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
| US8445649B2 (en) * | 2007-10-29 | 2013-05-21 | Tao Health Life Pharma Co., Ltd. | Antibody and use thereof |
| JP5386369B2 (ja) * | 2007-12-12 | 2014-01-15 | 株式会社 免疫生物研究所 | アルツハイマー病の存在又は傾向の診断薬及び診断方法 |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| RU2689674C2 (ru) * | 2012-10-15 | 2019-05-28 | Медиммьюн Лимитед | Антитела к бета-амилоиду |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| TW201740944A (zh) | 2016-03-15 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
| KR20180119670A (ko) | 2016-03-15 | 2018-11-02 | 아스트라제네카 아베 | 아밀로이드 베타의 축적과 관련된 질환의 치료를 위한 bace 억제제와 항체 또는 항원 결합 단편의 조합 |
-
2013
- 2013-10-15 RU RU2018110064A patent/RU2689674C2/ru active
- 2013-10-15 BR BR112015008347-1A patent/BR112015008347B1/pt active IP Right Grant
- 2013-10-15 EP EP13805277.4A patent/EP2906597B1/en active Active
- 2013-10-15 KR KR1020157012631A patent/KR102308915B1/ko active IP Right Grant
- 2013-10-15 JP JP2015536189A patent/JP6343615B2/ja active Active
- 2013-10-15 CA CA2888322A patent/CA2888322A1/en active Pending
- 2013-10-15 KR KR1020217031163A patent/KR102450670B1/ko active IP Right Grant
- 2013-10-15 PL PL13805277T patent/PL2906597T3/pl unknown
- 2013-10-15 WO PCT/EP2013/071567 patent/WO2014060444A1/en active Application Filing
- 2013-10-15 PT PT138052774T patent/PT2906597T/pt unknown
- 2013-10-15 ME MEP-2020-119A patent/ME03751B/me unknown
- 2013-10-15 ES ES13805277T patent/ES2802873T3/es active Active
- 2013-10-15 AU AU2013333948A patent/AU2013333948B2/en active Active
- 2013-10-15 SI SI201331737T patent/SI2906597T1/sl unknown
- 2013-10-15 CN CN201910295599.9A patent/CN110294804B/zh active Active
- 2013-10-15 CN CN201380053909.7A patent/CN105164156B/zh active Active
- 2013-10-15 HU HUE13805277A patent/HUE051127T2/hu unknown
- 2013-10-15 EP EP20160286.9A patent/EP3721942A1/en active Pending
- 2013-10-15 DK DK13805277.4T patent/DK2906597T3/da active
- 2013-10-15 MX MX2015004763A patent/MX370725B/es active IP Right Grant
- 2013-10-15 RS RS20200694A patent/RS60388B1/sr unknown
- 2013-10-15 RU RU2015118180A patent/RU2651486C2/ru active
- 2013-10-15 US US14/435,520 patent/US9834598B2/en active Active
- 2013-10-15 LT LTEP13805277.4T patent/LT2906597T/lt unknown
-
2015
- 2015-04-15 MX MX2019015602A patent/MX2019015602A/es unknown
-
2016
- 2016-02-17 HK HK16101678.9A patent/HK1213906A1/zh unknown
-
2017
- 2017-10-25 US US15/793,510 patent/US10662239B2/en active Active
-
2018
- 2018-05-21 JP JP2018096788A patent/JP6669805B2/ja active Active
- 2018-10-30 AU AU2018256498A patent/AU2018256498B2/en active Active
-
2020
- 2020-02-27 JP JP2020031419A patent/JP6959377B2/ja active Active
- 2020-05-01 US US16/864,439 patent/US11286297B2/en active Active
- 2020-06-10 HR HRP20200936TT patent/HRP20200936T1/hr unknown
- 2020-06-11 CY CY20201100538T patent/CY1122987T1/el unknown
- 2020-10-16 AU AU2020256414A patent/AU2020256414B2/en active Active
-
2021
- 2021-10-07 JP JP2021165338A patent/JP7301924B2/ja active Active
-
2022
- 2022-02-16 US US17/673,449 patent/US20220251181A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101375A patent/JP2023116770A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018110064A (ru) | Антитела к бета-амилоиду | |
| JP2013542194A5 (ru) | ||
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| JP2015514110A5 (ru) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018536393A5 (ru) | ||
| JP2015535828A5 (ru) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2014534239A5 (ru) | ||
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| JP2015503909A5 (ru) | ||
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2011502137A5 (ru) | ||
| HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| JP2015513903A5 (ru) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| HRP20161587T1 (hr) | Protutijela protiv bmp-6 | |
| JP2024024114A5 (ru) |